The Nucleofector® Technology offers a higher transfection efficiency than other non-viral transfection methods (including traditional electroporation1) along with other significant advantages outlined below.
With its superior transfection performance, Nucleofection offers various advantages over traditional electroporation methods:
- High transfection efficiencies of up to 90% for plasmid DNA and 99% for oligonucleotides, like siRNA.
- Excellent preservation of the physiological status and viability of transfected cells.
- Analysis of transfection results already shortly after transfection possible.
- Easy to use technology, with over 650 cell-type specific protocols that have led to direct transfection success.
- Transfection of a wide range of substrates, including DNA, mRNA, miRNA, siRNA, peptides or proteins.
- Transfection of hard-to-transfect cells, including primary cells, stem cells, neurons and cell lines, as well as cells in adherence.
Additionally, using Nucleofector® Technology can bring various practical benefits to your research, including:
- Reliance on a proven, reliable and innovative technology, that has featured in more than 8000 peer-reviewed publications worldwide
- Reduced risk of cross-contamination using the disposable sterile Nucleocuvette® Vessels
- Excellent technical and applicative support from a highly-skilled, specialist scientific support team
- Easy expansion of your research due to the flexible scaling capabilities of the different Nucleofector® Platforms, including low-, medium- and high-throughput transfection and easy transference of conditions between different device platforms.
These benefits can facilitate numerous applications, such as therapeutic gene knock-down via RNAi2 or CRISPR3 and the generation of induced pluripotent stem cells4 or CAR-T5, among many others. It is therefore not surprising that Nucleofector® Technology is now used in many different lines of research, including functional and structural genomics, drug discovery, and gene and cell therapy.
1 Maasho et al 2004 Journal of Immunological Methods
2 Marques and Williams, 2005 Nature Biotechnology